Thalidomide

Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.

Product Specifications

CAS Number

[50-35-1]

UNSPSC

12352005

Hazard Statement

H301, H312, H360

Target

Apoptosis; Autophagy; Ligands for E3 Ligase; Molecular Glues

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/thalidomide.html

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(C2CCC(NC2=O)=O)C(C3=CC=CC=C31)=O

Molecular Formula

C13H10N2O4

Molecular Weight

258.23

Precautions

H301, H312, H360

References & Citations

[1]Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512 (7512) :49-53.|[2]Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203.|[3]Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018 Dec;129:446-453.